1801379-22-5
1801379-22-5
Chemical Structure
DPLG3
- CAS No.: 1801379-22-5
- Formula:C37H41FN4O5
- Molecular Weight:640.74
InChIKey: DDEQIWLWJUDFKG-ACHIHNKUSA-N
SMILES: FC(C=C1)=CC=C1C[C@H](NC([C@H](CC(NOC(C)(C)C)=O)NC(CCC2=CC=CC=C2)=O)=O)C(NCC3=CC=CC4=C3C=CC=C4)=O
Biological Activity: DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DPLG3 | 99.18% | DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Moallemian R, et al. Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochem Pharmacol. 2020 Jul;177:113964. [Content Brief]
- [2]. Sula Karreci E, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8425-E8432. [Content Brief]
- [3]. Basler M, et al. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019 Mar;71(3):263-271. [Content Brief]
